Published in Hepatology on June 01, 2003
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology (2011) 1.87
A perspective on modelling hepatitis C virus infection. J Viral Hepat (2010) 1.67
Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend (2008) 1.60
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol (2011) 1.47
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology (2005) 1.26
Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol (2009) 1.22
Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it. World J Gastroenterol (2008) 1.11
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology (2009) 1.11
Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A (2009) 1.08
Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol (2006) 1.08
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther (2012) 1.07
Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters. J Viral Hepat (2008) 1.06
Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol (2010) 1.02
Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J Gastroenterol (2006) 1.01
Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr (2009) 0.94
Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol (2009) 0.92
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can J Gastroenterol (2008) 0.91
Viral kinetics of enterovirus 71 in human abdomyosarcoma cells. World J Gastroenterol (2011) 0.91
Hepatitis C Viral Kinetics in Special Populations. Curr Hepat Rep (2008) 0.90
Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat (2011) 0.88
Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation (2012) 0.87
IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. J Infect Dis (2011) 0.87
Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. J Natl Med Assoc (2005) 0.87
Viral kinetics in hepatitis C. Hepatology (2003) 0.86
Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis (2009) 0.85
Demographics, socio-behavioral factors, and drug use patterns: what matters in spontaneous HCV clearance? J Med Virol (2012) 0.85
Viral kinetic modeling: state of the art. J Pharmacokinet Pharmacodyn (2014) 0.85
Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int (2007) 0.84
Current Treatment for Chronic Hepatitis C. Curr Treat Options Gastroenterol (2004) 0.80
Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Math Biosci (2013) 0.80
Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. Antimicrob Agents Chemother (2008) 0.79
Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response. Virol J (2007) 0.79
IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. Eur J Gastroenterol Hepatol (2012) 0.78
Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin. Med Sci Monit (2011) 0.77
Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy. PLoS One (2012) 0.76
Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients. Comp Hepatol (2005) 0.76
Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure. Dig Dis Sci (2007) 0.75
The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients. Gastroenterol Hepatol (N Y) (2007) 0.75
Viral kinetics and hepatitis C. Hepatology (2003) 0.75
HCV Kinetic Models and Their Implications in Drug Development. CPT Pharmacometrics Syst Pharmacol (2015) 0.75
Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients. Mem Inst Oswaldo Cruz (2014) 0.75
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Kinetics of influenza A virus infection in humans. J Virol (2006) 3.78
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol (2007) 3.24
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 2.95
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature (2004) 2.74
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
The complexity of complexes in signal transduction. Biotechnol Bioeng (2003) 2.20
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol (2003) 2.03
Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol (2010) 2.02
Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl (2006) 2.01
Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology (2007) 2.00
CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog (2010) 1.99
Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood (2012) 1.91
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol (2007) 1.89
Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (2011) 1.88
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology (2011) 1.87
Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol (2003) 1.87
Cutting edge: Experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion. J Immunol (2008) 1.82
In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A (2002) 1.82
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol (2010) 1.80
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol (2009) 1.78
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol (2010) 1.78
Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol (2004) 1.77
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
ON IDENTIFIABILITY OF NONLINEAR ODE MODELS AND APPLICATIONS IN VIRAL DYNAMICS. SIAM Rev Soc Ind Appl Math (2011) 1.69
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology (2006) 1.69
Polyspecificity of T cell and B cell receptor recognition. Semin Immunol (2007) 1.68
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol (2005) 1.60
The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood (2009) 1.59
Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol (2011) 1.57
Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol (2009) 1.56
Parameter identifiability and estimation of HIV/AIDS dynamic models. Bull Math Biol (2008) 1.56
Drug resistance and influenza pandemics. Lancet (2002) 1.55
Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.54
Estimating lymphocyte division and death rates from CFSE data. Bull Math Biol (2006) 1.53
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol (2008) 1.51
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Division-linked differentiation can account for CD8+ T-cell phenotype in vivo. Eur J Immunol (2009) 1.51
Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol (2008) 1.51
Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol (2008) 1.49
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A (2007) 1.48
Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology (2005) 1.47
Real time bayesian estimation of the epidemic potential of emerging infectious diseases. PLoS One (2008) 1.46
HIV-1 infection and low steady state viral loads. Bull Math Biol (2002) 1.46
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis (2002) 1.45
Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics (2010) 1.45
Th-1-type cytotoxic CD8+ T-lymphocyte responses to simian immunodeficiency virus (SIV) are a consistent feature of natural SIV infection in sooty mangabeys. J Virol (2006) 1.44
Agent-based modeling of host-pathogen systems: The successes and challenges. Inf Sci (Ny) (2009) 1.43
Multiplicity of human immunodeficiency virus infections in lymphoid tissue. J Virol (2004) 1.43
Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med (2008) 1.42
Complete genetic linkage can subvert natural selection. Proc Natl Acad Sci U S A (2007) 1.42
Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci (2002) 1.41
Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol (2006) 1.41
Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol (2008) 1.39
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol (2004) 1.39
Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology (2006) 1.38
HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci U S A (2005) 1.36
Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A (2011) 1.36
Quantifying T lymphocyte turnover. J Theor Biol (2013) 1.35
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol (2006) 1.31
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol (2002) 1.30
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS (2003) 1.30
Modeling the within-host dynamics of HIV infection. BMC Biol (2013) 1.29